Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

The goal of this clinical trial is to learn what dose of the drug fampridine can be given safely together with imatinib (Gleevec) in patients with gastrointestinal stromal tumor (GIST) with a DNA mutation in exon 11 of the KIT gene. The main questions this study aims to answer are: * What is the maximum dose of fampridine that can be given safely together with imatinib (Gleevec)? * Is the combination of the two drugs efficacious against the tumor? Participants will: * Take the drugs before tumor surgery (preoperative treatment) for at least 2 months with the option to continue for a longer period of time if treatment seems safe and effective. * Visit the clinic at the scheduled appointments for checkups and tests.

NCT Number	NCT07171203
Lead Sponsor	University of California, San Diego
Conditions	Gastrointestinal Stromal Tumors
Enrollment	18 participants
Start Date	2026-05-13
Primary Completion	2030-07 (estimated)
Study Completion	2031-07 (estimated)
Updated on ClinicalTrials.gov	2026-05-27